fls.txt
Actual events in the future could differ materially from those described in the forward-looking information.


item1.txt
The accompanying condensed consolidated financial statements include the accounts of Scientific Industries, Inc., Altamira Instruments, Inc. (“Altamira”), a Delaware corporation and wholly-owned subsidiary, Scientific Bioprocessing, Inc. (“SBI”), a Delaware corporation and wholly-owned subsidiary, and Scientific Packaging Industries, Inc., an inactive wholly-owned subsidiary (all collectively referred to as the “Company”).
The Company is currently evaluating the effect of the new standard.
In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230)”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents.
The Company is a fiscal-year end taxpayer and is required to use a blended statutory federal tax rate, inclusive of the Federal rate change enacted on December 22, 2017 to compute its effective rate for the three and six months ended December 31, 2017.
The various provisions under the 2017 Tax Act most relevant to the Company have been considered in the preparation of the financial statements as of March 31, 2018.
The Company estimates it will record a one-time non-cash charge of approximately $30,000 for the fiscal year ended June 30, 2018 due to an estimated reduction in deferred tax assets as a result of the reduction in the Federal tax rate.
Accounts receivable of $245,400 was reclassified from current to long-term assets on the balance sheet as of June 30, 2017 to conform to the current period's presentation.
Approximately 53% and 54% of net benchtop laboratory equipment sales (39% and 40% of total revenues) for the three month periods ended March 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 21% of total benchtop laboratory equipment sales (16% of total revenues) were derived from the Torbal Scales Division for both the three months ended March 31, 2018 and 2017, respectively.
For the three months ended March 31, 2018 and 2017, respectively, two customers accounted in the aggregate for approximately 17% and 15% of net sales of the Benchtop Laboratory Equipment Operations (13% and 11% of the Company’s total revenues).
Approximately 51% and 53% of net benchtop laboratory equipment sales (43% and 37% of total revenues) for the nine month periods ended March 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 22% and 23% of total benchtop laboratory equipment sales (19% and 16% of total revenues) were derived from the Torbal Scales Division for the nine months ended March 31, 2018 and 2017, respectively.
For the nine months ended March 31, 2018 and 2017, respectively, two customers accounted in the aggregate for approximately 16% of net sales of the Benchtop Laboratory Equipment Operations (14% and 11% of the Company’s total revenues).
Sales to three and four customers during the nine months ended March 31, 2018 and 2017, accounted for approximately 79% and 92% of the Catalyst Research Instrument Operations’ revenues and 4% and 24% of the Company’s total revenues, respectively.
The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.


item2.txt
The Company reflected a loss before income tax benefit of $83,900 for the three months ended March 31, 2018 compared to income before tax expense of $82,900 for the three months ended March 31, 2017, primarily due to increase in contingent consideration liability resulting from increased royalty revenues for the Bioprocessing Systems Operations.
The Company reflected a loss before income tax benefit of $374,100 for the nine months ended March 31, 2018 compared to income before income tax expense of $78,200 for the nine months ended March 31, 2017 mainly due to the increase in contingent consideration liability for the Bioprocessing Systems Operations and reduced income from the Catalyst Research Instruments Operations resulting from decreased catalyst research instrument sales.
The results reflected total non-cash amounts for depreciation, amortization and contingent consideration liability adjustments totaling $521,700 and $675,800 for the three and nine month periods ended March 31, 2018 compared to $87,100 and $276,500 for the corressponding three and nine month periods in 2017.
The overall gross profit percentage for the three months ended March 31, 2018 was 36.6% compared to 44.8% for the three months ended March 31, 2017 due to adjustment for increased contingent consideration from increased royalty revenues for the Bioprocessing Systems Operations.
General and administrative expenses increased by $35,100 (8.1%) to $470,200 for the three months ended March 31, 2018 compared to $435,100 for the three months ended March 31, 2017 due to various incremental increases across the three operational segments.
The Company reflected an income tax benefit of $46,200 for the three months ended March 31, 2018 compared to income tax expense of $17,300 for the three months ended March 31, 2017, primarily due to the loss for the period.
As a result of the foregoing, the Company recorded a net loss of $37,700 for the three months ended March 31, 2018 compared to net income of $65,600 for the three months ended March 31, 2017.
General and administrative expenses for the nine months ended March 31, 2018 increased $49,900 (4.0%) to $1,306,600 compared to $1,256,700 for the nine months ended March 31, 2017 due to various incremental increases across the three operational segments.
Research and development expenses increased by $45,200 (13.5%) to $379,700 for the nine months ended March 31, 2018 compared to $334,500 for the nine months ended March 31, 2017, primarily due to increased new product development costs incurred by the Benchtop Laboratory Equipment Operations related to the Torbal Scales Division.
Total other income decreased by $7,200 (52.9%) to $6,400 for the nine months ended March 31, 2018 from $13,600 for the nine months ended March 31, 2018 due to a gain on a sale of investment securities last year.


item4.txt
As of the end of the period covered by this report, the Company's management performed an evaluation of the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934).


